- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 31/03 - Hydrocarbures halogénés carbocycliques aromatiques
Détention brevets de la classe A61K 31/03
Brevets de cette classe: 322
Historique des publications depuis 10 ans
|
15
|
18
|
26
|
21
|
29
|
19
|
28
|
49
|
45
|
12
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Corcept Therapeutics, Inc. | 330 |
8 |
| The Regents of the University of Michigan | 4660 |
6 |
| The Johns Hopkins University | 5628 |
6 |
| Bio-Pharm Solutions Co., Ltd. | 60 |
6 |
| ChemoCentryx, Inc. | 388 |
6 |
| The Regents of the University of California | 19784 |
4 |
| Neuropro Therapeutics, Inc. | 20 |
4 |
| Orion Corporation | 609 |
4 |
| Lunella Biotech, Inc. | 102 |
4 |
| GABA Therapeutics Inc. | 6 |
4 |
| Ben-Gurion University of the Negev Research and Development Authority | 208 |
3 |
| BioMendics, LLC | 12 |
3 |
| Gilead Sciences, Inc. | 2018 |
3 |
| Regents of the University of Minnesota | 2684 |
3 |
| Research Institute at Nationwide Children's Hospital | 551 |
3 |
| SK Biopharmaceuticals Co., Ltd. | 261 |
3 |
| St. Jude Children's Research Hospital | 245 |
3 |
| Washington University | 1593 |
3 |
| Relay Therapeutics, Inc. | 68 |
3 |
| Merck Sharp & Dohme LLC | 3738 |
3 |
| Autres propriétaires | 240 |